Squarepoint’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-17,825
| Closed | -$99.8K | – | 4825 |
|
|
2024
Q2 | $99.8K | Buy |
+17,825
| New | +$77.6K | ﹤0.01% | 3800 |
|
|
2024
Q1 | – | Sell |
-28,960
| Closed | -$151K | – | 4748 |
|
|
2023
Q4 | $151K | Buy |
28,960
+18,075
| +166% | +$178K | ﹤0.01% | 3674 |
|
|
2023
Q3 | $172K | Buy |
+10,885
| New | +$196K | ﹤0.01% | 3461 |
|
|
2023
Q2 | – | Sell |
-33,498
| Closed | -$950K | – | 4124 |
|
|
2023
Q1 | $950K | Sell |
33,498
-1,322
| -4% | -$39.2K | ﹤0.01% | 1930 |
|
|
2022
Q4 | $1.02M | Buy |
34,820
+10,910
| +46% | +$347K | ﹤0.01% | 1813 |
|
|
2022
Q3 | $632K | Buy |
23,910
+15,632
| +189% | +$574K | ﹤0.01% | 2084 |
|
|
2022
Q2 | $368K | Sell |
8,278
-1,192
| -13% | -$54.8K | ﹤0.01% | 2172 |
|
|
2022
Q1 | $469K | Buy |
9,470
+1,068
| +13% | +$51.3K | ﹤0.01% | 2049 |
|
|
2021
Q4 | $428K | Buy |
+8,402
| New | +$435K | ﹤0.01% | 2244 |
|
|
2021
Q3 | – | Sell |
-5,197
| Closed | -$222K | – | 3556 |
|
|
2021
Q2 | $222K | Buy |
+5,197
| New | +$214K | ﹤0.01% | 2745 |
|
|
2021
Q1 | – | Sell |
-8,381
| Closed | -$390K | – | 3729 |
|
|
2020
Q4 | $390K | Sell |
8,381
-4,953
| -37% | -$232K | ﹤0.01% | 2011 |
|
|
2020
Q3 | $566K | Buy |
13,334
+8,077
| +154% | +$353K | 0.01% | 1346 |
|
|
2020
Q2 | $252K | Sell |
5,257
-11,338
| -68% | -$566K | ﹤0.01% | 1707 |
|
|
2020
Q1 | $763K | Sell |
16,595
-15,964
| -49% | -$801K | 0.02% | 842 |
|
|
2019
Q4 | $1.96M | Buy |
32,559
+24,721
| +315% | +$1.47M | 0.01% | 920 |
|
|
2019
Q3 | $443K | Sell |
7,838
-18,771
| -71% | -$1.06M | ﹤0.01% | 1680 |
|
|
2019
Q2 | $1.48M | Sell |
26,609
-7,591
| -22% | -$396K | 0.01% | 1014 |
|
|
2019
Q1 | $1.73M | Sell |
34,200
-3,988
| -10% | -$177K | 0.02% | 841 |
|
|
2018
Q4 | $1.54M | Buy |
+38,188
| New | +$1.97M | 0.02% | 763 |
|
|
2018
Q2 | – | Sell |
-4,747
| Closed | -$250K | – | 2115 |
|
|
2018
Q1 | $250K | Sell |
4,747
-47,613
| -91% | -$2.77M | ﹤0.01% | 1400 |
|
|
2017
Q4 | $2.8M | Buy |
+52,360
| New | +$2.91M | 0.05% | 433 |
|
|
2017
Q3 | – | Sell |
-46,425
| Closed | -$3.66M | – | 1940 |
|
|
2017
Q2 | $3.66M | Buy |
46,425
+19,139
| +70% | +$1.57M | 0.07% | 336 |
|
|
2017
Q1 | $2.26M | Buy |
+27,286
| New | +$2.03M | 0.06% | 359 |
|
|
2016
Q4 | – | Sell |
-8,971
| Closed | -$628K | – | 1965 |
|
|
2016
Q3 | $628K | Sell |
8,971
-2,729
| -23% | -$151K | 0.04% | 489 |
|
|
2016
Q2 | $454K | Buy |
+11,700
| New | +$487K | 0.03% | 588 |
|
Other funds holding EGRX
NCM
ACM
Squarepoint's EGRX Position: Q3 2024 in Review
Squarepoint sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 17,825 shares — an estimated $99.8K sold.
Squarepoint first reported a position in EGRX in Q2 2016 and held it in 25 quarters. The position peaked at $3.66M in Q2 2017. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.
- Squarepoint reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- Squarepoint sold 17,825 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $99.8K.
- Squarepoint first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 25 quarters.
- Squarepoint's Eagle Pharmaceuticals, Inc. position peaked at $3.66M in Q2 2017.
- 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.
Based on Squarepoint's 13F filing for Q3 2024, filed 14 Nov 2024.